Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Tesla Says Production On Track For 50% Growth, But Delivery Just Under 50%

-Conference Call
byMichael Horton
October 19, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

-Conference Call

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Novartis Announced Kisqali Adds One More Year of Survival Benefit for Broadest Set of Patients, Including Those with Aggressive HR+/HER2- Advanced Breast Cancer

By Charles Gross
September 9, 4:59 AM
Novartis today announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.

NVS